Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Children's Hospital Los Angeles
Emory University
Novartis
Valent Technologies, LLC
Actuate Therapeutics Inc.
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Children's Hospital Los Angeles